Docetaxel Conjugate Lyophilized Powder Formulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing taxane drug compositions, such as docetaxel, face stability and safety issues due to the use of high amounts of surfactants and organic solvents, which lead to adverse reactions and reduced clinical safety.
Innovation Solution
A lyophilized powder composition of a docetaxel conjugate with a pharmaceutically acceptable carrier and a reconstitution solvent containing a small amount of surfactant, separated into different chambers, is developed to improve stability and safety by adjusting the pH value to 4.5-5.5 and minimizing surfactant use.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If high amounts of surfactants and organic solvents are used to improve docetaxel solubility, then the drug can be administered clinically, but safety issues and adverse reactions occur
Solution Approach 1:
The patent changes the pH parameter of the solution to 4.5-5.5, which fundamentally alters the solubility characteristics of docetaxel. At this acidic pH range, docetaxel achieves adequate solubility for clinical administration without requiring high concentrations of surfactants or organic solvents, thereby reducing adverse reactions while maintaining drug availability
Solution Approach 2:
The patent employs a disposable lyophilized powder formulation that is reconstituted immediately before use. This approach eliminates the need for stable, surfactant-containing solutions that would require long-term storage, allowing the use of minimal surfactant quantities that are sufficient only for the brief reconstitution and administration process
2Quantity of substance
If surfactants are used to increase drug solubility in injectable formulations, then the drug can be dissolved and administered, but allergic and hemolytic side effects occur
Solution Approach 1:
By adjusting the pH to 4.5-5.5, the patent fundamentally changes the solubility behavior of docetaxel, enabling the drug to achieve adequate solubility with minimal or no surfactant addition. This parameter change directly addresses the harmful effects of surfactants by making them unnecessary for achieving clinical solubility requirements
Solution Approach 2:
The patent extracts or removes surfactants from the formulation by utilizing the acidic pH environment that inherently provides sufficient solubility for docetaxel. This extraction of the harmful component (surfactant) eliminates the source of allergic and hemolytic side effects while maintaining drug solubility through pH-dependent solubility characteristics
3Ease of operation
If ethanol is added to promote drug reconstitution, then the drug dissolves more effectively, but the toxicity of organic solvents increases
Solution Approach 1:
The patent changes the pH parameter to 4.5-5.5, which fundamentally alters the reconstitution characteristics of docetaxel. At this acidic pH, the drug achieves effective dissolution upon contact with aqueous reconstitution fluids without requiring ethanol or other toxic organic solvents, thereby eliminating solvent toxicity while maintaining ease of reconstitution
Solution Approach 2:
The lyophilized powder formulation is designed for single-use reconstitution immediately before administration. This disposable approach allows the use of simple, non-toxic reconstitution fluids without ethanol, as the formulation is discarded after a single use, eliminating the need for toxic organic solvents that would be required for stable solutions
4Quantity of substance
If non-ionic surfactants are used in injectable formulations, then drug solubility is improved, but hemolytic properties and serious side effects occur with large quantities
Solution Approach 1:
By adjusting the pH to 4.5-5.5, the patent fundamentally changes the solubility characteristics of docetaxel, enabling the drug to achieve adequate solubility without requiring large quantities of non-ionic surfactants. This parameter change directly improves clinical safety by eliminating the need for high surfactant concentrations that cause hemolytic effects and serious side effects
Solution Approach 2:
The patent extracts or removes the need for large quantities of non-ionic surfactants by utilizing the acidic pH environment that provides inherent solubility enhancement. This extraction of the harmful component (large quantities of surfactant) eliminates the source of hemolytic side effects and improves formulation reliability while maintaining adequate drug solubility
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The solution significantly enhances the stability and safety of docetaxel, reducing adverse reactions and extending the shelf life of the drug, while maintaining effective antitumor activity.
Implementation Method 1
a lyophilized powder composition of a docetaxel conjugate
Data Source
Figure 1~2
Figure 3~4B
Figure 5~5B
AI summary
The present invention belongs to the field of pharmaceutical manufacturing technology. The present invention provides a pharmaceutical composition of a conjugate and a preparation method thereof. The pharmaceutical composition is preferably administered by injection. The docetaxel conjugate has a structural formula as shown in the following formula: (I).